Amarin Corporation plc (NASDAQ: AMRN) is one of the best performing pharma stocks in 2025, achieving positive cash flow in fiscal Q4 2025 and securing a partnership with Recordati S.p.A. The company anticipates sustainable positive annual cash flow in 2026 with a year-end 2025 cash balance of $303 million. Fiscal year 2025 net revenue is projected to be in the range of $212 to $217 million. Amarin Corporation plc focuses on cardiovascular health therapeutics, particularly Vascepa capsules. While AMRN shows promise as an investment, certain AI stocks may offer greater potential.

Read more at Yahoo Finance: Amarin Corporation (AMRN) Announces Select Unaudited Financial Highlights